Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)
GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.
GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.
Newborn screening for genetic predisposition of type 1 diabetes using a polygenic 51 SNP risk score
Freder1k study
Primary prevention study to determine whether vaccinating children with an elevated genetic risk for type 1 diabetes against SARS-CoV influences immune development, beta-cell function, and the risk of islet autoimmunity
AVAnT1A study
Primary intervention study to determine whether daily administration of B. infantis EVC001 until age 12 months to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in childhood
SINT1A study
Primary intervention study to determine whether daily administration of oral insulin to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies and diabetes in childhood
POInT study
Contact
![[Translate to German:]](https://images.admiralcloud.com/v5/deliverEmbed/a4d7386e-8c04-41d8-aa70-d9757f2596b2/image_png/cropperjsfocus/256/256/246.0260247564937,180.77925882711043,1536.0000000000002,1536.0000000000002,0,1,1/768,768?poc=true "[Translate to German:]")